UI Investissement & Bpifrance take majority stake in Theradial
Context
Théradial has completed a shareholder restructuring agreement, welcoming UI Gestion and Bpifrance as new majority shareholders. This transaction is part of a management buy-out, enabling Frédéric Le Pottier, the former Commercial Director, to take the helm as Chairman of the Executive Board. Meanwhile, Bruno Duval, the company's founder, will retain a key role as a shareholder and become Chairman of the Supervisory Board. The goal of this transaction is to support Théradial's growth strategy, which aims to leverage its pharmaceutical establishment status, obtained two years ago, to expand its product portfolio. Currently, Théradial is primarily focused on hemodialysis equipment but has already begun diversifying into oncology, nutrition, and gastroenterology. This deal was facilitated by specialized advisors, including Deloitte, Ariane Santé Social, and De Pardieu Brocas Maffei, who conducted financial, strategic, and legal due diligence. Senior lenders LCL, Société Générale, and CIC provided financial support for the transaction.
Theradial, which reported an EBITDA margin of [members only] in 2017, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x in 2026).
-> Deep-dive in Healthcare & Pharma market trends
Target
Theradial, a medical device distribution firm focused on dialysis equipment, has undergone substantial development over the years. Initially concentrated on supplying medical devices to public health institutions, private clinics, and home care providers, the company gradually expanded its scope of activities. It now offers medications and software tailored to dialysis centers, enabling it to address the specific needs of its clients. By diversifying its product portfolio, Theradial has enhanced its capability to cater to a broader range of customers. The company has also collaborated with pharmaceutical laboratory Indigo Therapeutics to develop nutritional supplements for patients undergoing dialysis, thereby broadening its offerings to include complementary healthcare products. This strategic move has allowed Theradial to deepen its understanding of the dialysis treatment process and provide more comprehensive solutions to its customers, ultimately refining its operational capabilities and reinforcing its position in the medical device distribution sector.
Ent. Value
[members only]
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Theradial
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 02/2023 | ARDIAN | THERADIAL | FRANCE | Medical Devices |
| 03/2019 | THERADIAL | GROUPE THÉMA | FRANCE | Healthcare |
Other operations with UI Investissement / Bpifrance
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2026 | UI INVESTISSEMENT | FINASENS | FRANCE | Accounting & Audit |
| 01/2026 | UI INVESTISSEMENT | MAISON ALSACIENNE DE BISCUITERIE | FRANCE | Fine Food / Organic |
| 07/2025 | UI INVESTISSEMENT / MACSF / COVEA | ADIT (AGENCE POUR LA DIFFUSION DE L'INFORMATION TECHNOLOGIQUE) | FRANCE | Consulting & Audit |
| 12/2024 | UI INVESTISSEMENT | DIDACTIC | FRANCE | Medical Consumables |
| 11/2024 | UI INVESTISSEMENT | ANTARES DIFFUSION | FRANCE | Aftermarket & Repair |
| 06/2022 | UI INVESTISSEMENT / GENEO | NEFTYS PHARMA | FRANCE | Animal Health |
| 01/2015 | UI INVESTISSEMENT | GAULT & FRÉMONT | FRANCE | Paper & Cardboard |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 05/2018 | PERMIRA | CORIN GROUP | UNITED KINGDOM | Implants & Prosthetics |
| 12/2017 | PERKINELMER | EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS | GERMANY | Diagnostic Equipment |
| 10/2017 | CVC | SEBIA | FRANCE | Diagnostic Equipment |
| 09/2017 | FRESENIUS | NXSTAGE MEDICAL | UNITED STATES | Diagnostic Equipment |
| 06/2017 | EQT PARTNERS | OTTOBOCK | GERMANY | Implants & Prosthetics |
| 06/2017 | CHARTERHOUSE | SERB | BELGIUM | Pharma & Biotech |
| 05/2017 | PAI PARTNERS | ELITECH GROUP | FRANCE | Diagnostic Equipment |
| 04/2017 | BAIN CAPITAL / CINVEN | STADA | GERMANY | Generics / Labs |
| 04/2017 | NORDSON CORPORATION | VENTION ADVANCED TECHNOLOGIES | UNITED KINGDOM | Medical Devices |
| 03/2017 | ARDIAN | UNITHER | FRANCE | CDMO |
REFERENCES
Revenue range: REV €10–30M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Theradial by UI Investissement / Bpifrance are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: theradial
Acquirer: ui investissement / bpifrance
FAQ
What transaction does this page cover?
What was Theradial’s revenue at the time of the deal?
How does the valuation of Theradial compare to benchmarks in the Healthcare & Pharma sector?
What sources support the information on this transaction?
What is mynth?